Abstract:Introduction: The clinicopathologic features and prognostic predictors of radiological part-solid lung adenocarcinomas were unclear. Methods: We retrospectively compared the clinicopathologic features and survival times of part-solid tumors with those of pure ground glass nodules (pGGNs) and pure solid tumors treated with surgery at Fudan University Shanghai Cancer Center and evaluated the prognostic implications of consolidation-to-tumor ratio (CTR), solid component size, and tumor size for part-solid lung adenocarcinomas. Results: A total of 911 patients and 988 pulmonary nodules (including 329 part-solid nodules [PSNs], 501 pGGNs, and 158 pure solid nodules) were analyzed. More female patients (p = 0.015) and nonsmokers (p = 0.003) were seen with PSNs than with pure solid nodules. The prevalence of lymphatic metastasis was lower in patients with PSNs than in those with pure solid tumors (2.2% versus 27% [p < 0.001]). The 5-year lung cancer-specific (LCS) recurrence-free survival and LCS overall survival of patients with PSNs were worse than those of patients with pGGNs (p < 0.001 and p = .042, respectively) but better than those of patients with pure solid tumors ([p < 0.001 and p < 0.0001, respectively]). CTR (OR = 12.90; 95% confidence interval [CI]: 1.85-90.04), solid component size (OR = 1.45; 95% CI: 1.28-1.64), and tumor size (OR = 1.23; 95% CI: 1.15-1.31) could predict pathologic invasive adenocarcinoma for patients with PSNs. None of them could predict the prognosis. Patients receiving sublobar resection had prognoses comparable to those of patients receiving lobectomy (p = .178 for 5-year LCS recurrence-free survival and p = .319 for 5-year LCS overall survival). The prognostic differences between patients with systemic lymph node dissection and those without systemic lymph node dissection were statistically insignificant. Conclusions: Part-solid lung adenocarcinoma showed clinicopathologic features different from those of pure solid tumor. CTR, solid component size, and tumor size could not predict the prognosis. Part-solid lung adenocarcinomas define one special clinical subtype. (C) 2019 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.

Solid component and tumor size correlate with prognosis of stage IB lung adenocarcinoma.

[Analysis of the Effect of Different Pathological Subtypes to Prognosis in Stage I Pulmonary Adenocarcinoma].

Influences of Tumor Size and Pleural Layer Invasion on the Prognosis of Patients with Stage IB Lung Adenocarcinoma

The Clinical Prognostic Factors of Patients with Stage IB Lung Adenocarcinoma.

Solid Component Ratio Influences Prognosis of GGO-featured IA Stage Invasive Lung Adenocarcinoma

Histopathologic Pattern and Molecular Risk Stratification Are Associated with Prognosis in Patients with Stage IB Lung Adenocarcinoma

Impact of Solid Minor Histologic Subtype in Postsurgical Prognosis of Stage I Lung Adenocarcinoma.

Micropapillary or solid component predicts worse prognosis in pathological IA stage lung adenocarcinoma: A meta-analysis

A Comprehensive Evaluation of Clinicopathologic Characteristics, Molecular Features and Prognosis in Lung Adenocarcinoma with Solid Component.

Meta-analysis of Comparing Part-Solid and Pure-Solid Tumors in Patients with Clinical Stage IA Non-Small-cell Lung Cancer in the Eighth Edition TNM Classification

Correlation of Survival and EGFR Mutation with Predominant Histologic Subtype According to the New Lung Adenocarcinoma Classification in Stage IB Patients

Solid Component Proportion is an Important Predictor of Tumor Invasiveness in Clinical Stage T1N0M0 (ct1n0m0) Lung Adenocarcinoma

Distinct Prognostic Factors in Patients with Stage I Non–Small Cell Lung Cancer with Radiologic Part-Solid or Solid Lesions

The Prognostic and Predictive Value of Solid Subtype in Invasive Lung Adenocarcinoma

Lung Adenocarcinomas Manifesting As Radiological Part-Solid Nodules Define a Special Clinical Subtype.

Impact of a Ground-glass Opacity Component on C-Stage IA Lung Adenocarcinoma

Why Do Pathological Stage IA Lung Adenocarcinomas Vary from Prognosis?: a Clinicopathologic Study of 176 Patients with Pathological Stage IA Lung Adenocarcinoma Based on the IASLC/ATS/ERS Classification.

Tumor Size As a Predictor for Prognosis of Patients with Surgical IIIA-N2 Non-Small Cell Lung Cancer after Surgery.

Long-term prognostic characteristics of patients with clinical stage IA part-solid lung adenocarcinoma: a conditional survival analysis

Prognostic Significance of the IASLC/ATS/ERS Classification in Chinese Patients—a Single Institution Retrospective Study of 292 Lung Adenocarcinoma

Preoperative Prognostic Prediction for Stage I Lung Adenocarcinomas: Impact of the Computed Tomography Features Associated with the New Histological Grading System